... type, I was also not going to sit idly by and let someone else coordinate my medical care and I still refuse to do that. After establishing care with oncology and being started on Octreotide LAR injections, ...

The results from the first randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.
PRRT while available ...

... taking a stool softener with you (Senokot S is especially good), in case you need it. It’s also advisable to take pain meds with you, just in case you need them.
You’ll need to take your Octreotide subcutaneous ...

BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine ...

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open ...

... Barnes Jewish Hospital in St. Louis, Missouri. My new doctor there ordered several tests for me including the Octreotide scan, CT scan, and blood tests. My tumors were confirmed as Carcinoid with high ...

... and some suggested waiting and watching the disease since a medication called octreotide controlled all of Flora's symptoms. Most surgeons felt that Flora's cancer was inoperable because there were too m ...

... when the tumor burden is still minimal and the radiation therapy can be most effective. Download this article by Doctors Grabowski and Baum for more explanation.
Can I be on Octreotide therapy during ...

... diarrhea; weight gain in underweight patients; the ability to give up octreotide therapy; and improvement of overall health.
Most importantly, the median overall survival of patients from the start o ...

... xt, I emailed Josh to ask him how to contact the doctor and he copied his response to Dr. Baum. Within a day I had an email from the doctor telling me to get a new Octreotide scan and to send all of my rec ...

... to regress and die.
In studies by Dr. Kwekkeboom and his colleagues, the duration of therapy response for Y-90 octreotide and for Lu-177 octreotate is reported at more than 30 months.
Overall Surviva ...

... a form of octreotide) is combined with a radionuclide such as Lutetium-177 (LU177) or Yttrium-90 (Y90), it has a strong affinity for the somatostatin receptor subtype-2 that can exist in the NET tumor. ...

... tumors 2cm and larger.
In the late 1990s and early 2000s, Doctors started using two other radionuclides that were coupled to Octreotide. These were Yttrium-90 and Lutetium-177. Later some doctors tried ...

... as the magnet and the iron shavings are a somatatostatin analog chemical (Octreotide) to which is bound or attached to some radioactive material (the radionuclide Y90 or LU177). The receptors in the tumors ...

...
If the patient is using the Subq form of Octreotide up until the Saturday priot to PRRT, then the patient should bring that medication. It is also suggested that the patient bring some form of anti-nausea ...

... CT, MRI or Octreotide scans that should exist on CD or DVDs.
Depending upon a patient's case history, some historical records could be needed as well. Dr. Baum normally will advise the patient or th ...

Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (a somatostatin analog similar to octreotide) that is coupled with a ...